打妈护婴

来源: 于 2022-11-19 07:34:19 [博客] [旧帖] [给我悄悄话] 本文已被阅读：次

After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year

https://www.cnn.com/2022/11/01/health/rsv-vaccine-pfizer-fda

Pfizer says it has enough promising data on its respiratory syncytial virus, or RSV, vaccine designed to protect newborns that it will end enrollment in the study and submit for US Food and Drug Administration approval by the end of the year.

RSV is a common respiratory virus that typically causes mild, cold-like symptoms, but it can cause serious illness, particularly in older adults and infants. Pfizer’s vaccine candidate is administered to pregnant women who then make antibodies that cross the placenta and protect the baby after birth.

 

 

 

 

PS

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global